ClinicalTrials.gg
CompletedNCT05243680AGILEUpdated Jan 15, 2026Results posted

An Open-Label Extension Study of GSK3511294 (Depemokimab) in Participants Who Were Previously Enrolled in 206713 (NCT04719832) or 213744 (NCT04718103)

A Phase 3 interventional study of GSK3511294 (Depemokimab) in Asthma, sponsored by GlaxoSmithKline. Completed at 137 sites in 14 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-01-15.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
641
Allocation
Not applicable
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing depemokimab in Asthma — 3 open to participants now, 3 under way, 3 of them phase 3. depemokimab · Asthma.

Enrollment
2nd of 10
641 · median 273
Started
2022
with 1 other
Phase 3
7 of 10
3 open now
Registered
6th of 10
by date
Lead sponsor
10 of 10
GlaxoSmithKline

Among the 10 studies testing depemokimab in Asthma, this one is the 2nd largest by enrollment, is one of 2 that started in 2022, is one of 7 in phase 3, and was the 6th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

3 of the 10 studies testing depemokimab in Asthma are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About depemokimab

depemokimab: first FDA approval 2025 (EXDENSUR), first EMA approval 2026. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing depemokimab in Asthma, or all of them as a file.
02

Study summary

The purpose of this open-label 12-month extension study is to continue to characterize the long-term safety, efficacy and immunogenic profile of GSK3511294 (Depemokimab) in participants with severe asthma with an eosinophilic phenotype following completion of clinical studies 206713 or 213744.

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • GSK3511294
  • Depemokimab
  • Asthma
  • Long-term safety
  • Open-label
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants who completed the double-blind study intervention treatment during Study 206713 or Study 213744.
  • Participants capable of giving signed /assent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol. In France, a participant will be eligible for inclusion in this study only if either affiliated to or a beneficiary of a social security category.

Exclusion criteria

Exclusion criteria:

  • change in health status during Study 206713 or Study 213744 which in the opinion of the investigator would make the participant unsuitable for participation in this study.
  • A current or a malignancy that developed during Study 206713 or Study 213744 (participants who had localized carcinoma of the skin that was resected for cure will not be excluded).
  • Participants who have other clinically significant medical conditions uncontrolled with Standard of Care (SoC) therapy not associated with Asthma, for example (e.g.), uncontrolled cardiovascular disease or ongoing active infectious disease which in the opinion of the investigator makes them unsuitable for the study.
  • Participants with known parasitic (helminth) infections within 6 months prior to Visit 1 will be excluded from the study or required to be adequately treated for helminth infections before initiation of GSK3511294.
  • Participants who meet the following based on results of Week 48 assessment from Study 206713 or Study 213744 or from a later result:

    1. (ALT) greater than (>)2 times (ULN).
    2. Total >1.5 times ULN (isolated bilirubin >1.5 times ULN is acceptable if bilirubin is fractionated and direct bilirubin less than [\<] 35 percent [%]).
    3. Cirrhosis or current unstable liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, persistent jaundice.
  • Participants with current diagnosis of vasculitis. Participants with high clinical suspicion of vasculitis at screening will be evaluated and current vasculitis must be excluded prior to enrolment.
  • (ECG) assessment: corrected by Fridericia's formula (QTcF) greater than or equal to (>=)450 milliseconds (msec) or QTcF >=480 msec for participants with Bundle Branch Block at Visit 1.
  • Current smokers.
  • Participants with allergy/intolerance to the of GSK3511294, a monoclonal antibody, or biologic.
  • Participants who are pregnant or breastfeeding. Participants should not be enrolled if they plan to become pregnant during the time of study participation.
  • Participants who for any reason permanently discontinued study treatment in the previous study 206713/213744 will be excluded from this study.
  • Other product/clinical study:

    1. Participants who have received treatment with an investigational agent (biologic or non-biologic) within the past 30 days or 5 drug half-lives whichever is longer, prior to the first dose, other than Study 206713/213744 study treatment. The term "investigational" applies to any drug not approved for sale for the disease/indication to treat in the country in which it is being used or investigational formulations of marketed products.
    2. Participants who are currently participating in any other interventional clinical study.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
641 participants (actual)

Study arms

  • Experimental
    Participants diagnosed with asthma receiving GSK3511294 (Depemokimab)

    Biological: GSK3511294 (Depemokimab)

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Any Adverse Events (AEs) and Serious AEs (SAEs)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is any untoward medical occurrence that, at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or any other situation according to medical or scientific judgment.

    Time frame: Up to Week 56

  2. Number of Participants With Worst Case Post-Baseline Positive Anti-GSK3511294 Antibodies (ADA)

    Serum samples were collected for the determination of anti-GSK3511294 antibodies (ADA) using a validated electro-chemiluminescent immunoassay. The assay involved screening, confirmation and titration assays. If serum samples tested positive in the screening assay, they were considered 'potentially positive' and were further analyzed for specificity using the confirmation assay. Samples that confirmed positive in the confirmation assay were reported as 'positive'. Confirmed positive ADA samples were further characterized in the titration assay to quasi-quantitate the amount of ADA in the sample and were also further characterized in the Neutralizing antibody (Nab) assay. A participant was considered positive ADA if they had at least one positive worst case post-Baseline ADA result. Number of participants with worst case post-Baseline positive anti-GSK3511294 antibodies are presented.

    Time frame: Up to Week 52

  3. Number of Participants With Worst Case Post-Baseline Positive Neutralizing Antibodies

    Blood samples were collected for the determination of positive neutralizing antibodies. Neutralizing antibody (NAb) test was only carried out on samples that were positive in the confirmatory binding antibody assay. A participant was considered positive for NAb if they had at least one positive worst case post-Baseline neutralizing antibody result. Number of participants with worst case post-Baseline positive neutralizing antibodies are presented.

    Time frame: Up to Week 52

Secondary outcomes

  1. Annualized Rate of Clinically Significant Exacerbations

    Clinically significant exacerbations recorded were defined as worsening of asthma requiring the use of systemic corticosteroids (CS) (such as intramuscular \[IM\], intravenous \[IV\] or oral) and/or hospitalization and/or Emergency Department (ED) visit. For all participants, IV or oral steroids (e.g., prednisone) for at least 3 days or a single IM corticosteroid dose is required. For participants on maintenance systemic corticosteroids, at least double the existing maintenance dose for at least 3 days is required. Exacerbations recorded in the electronic case report form (eCRF) were considered as verified clinically significant exacerbations and included in the analysis. Exacerbations separated by less than 7 days was treated as a continuation of the same exacerbation.

    Time frame: Up to Week 52

  2. Change From Baseline in Asthma Control Questionnaire-5 (ACQ-5) Score

    The ACQ-5 is a five-item questionnaire developed as a measure of participants asthma symptom control. The questions are designed to be self-completed by the participant. The 5 questions enquired to recall how their asthma had been during the previous week and to respond about the frequency and/or severity of symptoms (nocturnal awakening, waking in the morning, activity limitation, shortness of breath and wheezing). The overall ACQ-5 response option is the mean score of all 5 questions representing 0 with no impairment/limitation and 6 as total impairment/ limitation. Higher scores indicated more limitations and lower score with better asthma control. Baseline was the value at Day 1 of the study. Change from Baseline was defined as value at the indicated time point minus Baseline value. Number of participants with analyzable data for one or more timepoints.

    Time frame: Baseline (Day 1), Weeks 4, 8, 12, 20, 26, 28, 32, 40 and 52

  3. Change From Baseline in St. George's Respiratory Questionnaire (SGRQ) Total Score at Weeks 26 and 52

    The SGRQ is a 50-item patient-reported outcome tool used to measure Quality of Life in participants with airway obstruction diseases. The questions are designed to be self-completed by the participant. The total score was calculated by the symptom score, activity and impact score; and summarizing the impact of the disease on overall health status on 0-100 rating scale. Scores are expressed as a percentage of overall impairment where 100 representing worst possible health status and 0 indicating best possible health status. Higher scores indicating greater impairment of quality of life. Baseline was the value at Day 1 of the study. Change from Baseline was defined as value at the indicated time point minus Baseline value. Number of participants with analyzable data for one or more timepoints.

    Time frame: Baseline (Day 1), Weeks 26 and 52

  4. Change From Baseline in Pre-Bronchodilator Forced Expiratory Volume in One Second (FEV1) at Weeks 26 and 52

    Forced Expiratory Volume in One Second (FEV1) is a measure of lung function and defined as the volume of air that can be forced out in one second after taking a deep breath. FEV1 was measured electronically by spirometry. Baseline was the value at Day 1 of the study. Change from Baseline in pre-bronchodilator FEV1 was defined as value at the indicated time point minus Baseline value. Number of participants with analyzable data for one or more timepoints.

    Time frame: Baseline (Day 1), Weeks 26 and 52

07

Results

Posted Jan 15, 2026

Participant flow

Participants who successfully completed treatment in studies 206713 (NCT04719832), and 213744 (NCT04718103) were eligible to continue their treatment in this open-label extension study 212895.

Participant flow — Overall Study
MilestonePlacebo in Previous Studies/GSK3511294 100 mg SC in Extension StudyGSK3511294 in Previous Studies/GSK3511294 100 mg SC in Extension Study
Started214427
Safety analysis set210419
Completed199403
Not completed1524
Withdrew: Adverse event11
Withdrew: Lack of efficacy11
Withdrew: Lost to follow-up54
Withdrew: Physician decision10
Withdrew: Withdrawal by subject310
Withdrew: Data integrity and gcp violations48

Outcome measures

PrimaryNumber of Participants With Any Adverse Events (AEs) and Serious AEs (SAEs)

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is any untoward medical occurrence that, at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or any other situation according to medical or scientific judgment.

Time frame:
Up to Week 56
Reported as:
Count of participants · Participants
Number of Participants With Any Adverse Events (AEs) and Serious AEs (SAEs)
ParticipantsPlacebo in Previous Studies/GSK3511294 100 mg SC in Extension StudyGSK3511294 in Previous Studies/GSK3511294 100 mg SC in Extension Study
Any AEs147301
Any SAEs2138
PrimaryNumber of Participants With Worst Case Post-Baseline Positive Anti-GSK3511294 Antibodies (ADA)

Serum samples were collected for the determination of anti-GSK3511294 antibodies (ADA) using a validated electro-chemiluminescent immunoassay. The assay involved screening, confirmation and titration assays. If serum samples tested positive in the screening assay, they were considered 'potentially positive' and were further analyzed for specificity using the confirmation assay. Samples that confirmed positive in the confirmation assay were reported as 'positive'. Confirmed positive ADA samples were further characterized in the titration assay to quasi-quantitate the amount of ADA in the sample and were also further characterized in the Neutralizing antibody (Nab) assay. A participant was considered positive ADA if they had at least one positive worst case post-Baseline ADA result. Number of participants with worst case post-Baseline positive anti-GSK3511294 antibodies are presented.

Time frame:
Up to Week 52
Reported as:
Count of participants · Participants
Number of Participants With Worst Case Post-Baseline Positive Anti-GSK3511294 Antibodies (ADA)
ParticipantsPlacebo in Previous Studies/GSK3511294 100 mg SC in Extension StudyGSK3511294 in Previous Studies/GSK3511294 100 mg SC in Extension Study
Number of Participants With Worst Case Post-Baseline Positive Anti-GSK3511294 Antibodies (ADA)1540
PrimaryNumber of Participants With Worst Case Post-Baseline Positive Neutralizing Antibodies

Blood samples were collected for the determination of positive neutralizing antibodies. Neutralizing antibody (NAb) test was only carried out on samples that were positive in the confirmatory binding antibody assay. A participant was considered positive for NAb if they had at least one positive worst case post-Baseline neutralizing antibody result. Number of participants with worst case post-Baseline positive neutralizing antibodies are presented.

Time frame:
Up to Week 52
Reported as:
Count of participants · Participants
Number of Participants With Worst Case Post-Baseline Positive Neutralizing Antibodies
ParticipantsPlacebo in Previous Studies/GSK3511294 100 mg SC in Extension StudyGSK3511294 in Previous Studies/GSK3511294 100 mg SC in Extension Study
Number of Participants With Worst Case Post-Baseline Positive Neutralizing Antibodies05
SecondaryAnnualized Rate of Clinically Significant Exacerbations

Clinically significant exacerbations recorded were defined as worsening of asthma requiring the use of systemic corticosteroids (CS) (such as intramuscular \[IM\], intravenous \[IV\] or oral) and/or hospitalization and/or Emergency Department (ED) visit. For all participants, IV or oral steroids (e.g., prednisone) for at least 3 days or a single IM corticosteroid dose is required. For participants on maintenance systemic corticosteroids, at least double the existing maintenance dose for at least 3 days is required. Exacerbations recorded in the electronic case report form (eCRF) were considered as verified clinically significant exacerbations and included in the analysis. Exacerbations separated by less than 7 days was treated as a continuation of the same exacerbation.

Time frame:
Up to Week 52
Reported as:
Mean · Exacerbation per participant per year
Annualized Rate of Clinically Significant Exacerbations
Exacerbation per participant per yearPlacebo in Previous Studies/GSK3511294 100 mg SC in Extension StudyGSK3511294 in Previous Studies/GSK3511294 100 mg SC in Extension Study
Annualized Rate of Clinically Significant Exacerbations0.58 (0.45 to 0.73)0.55 (0.47 to 0.66)
SecondaryChange From Baseline in Asthma Control Questionnaire-5 (ACQ-5) Score

The ACQ-5 is a five-item questionnaire developed as a measure of participants asthma symptom control. The questions are designed to be self-completed by the participant. The 5 questions enquired to recall how their asthma had been during the previous week and to respond about the frequency and/or severity of symptoms (nocturnal awakening, waking in the morning, activity limitation, shortness of breath and wheezing). The overall ACQ-5 response option is the mean score of all 5 questions representing 0 with no impairment/limitation and 6 as total impairment/ limitation. Higher scores indicated more limitations and lower score with better asthma control. Baseline was the value at Day 1 of the study. Change from Baseline was defined as value at the indicated time point minus Baseline value. Number of participants with analyzable data for one or more timepoints.

Time frame:
Baseline (Day 1), Weeks 4, 8, 12, 20, 26, 28, 32, 40 and 52
Reported as:
Least squares mean · Scores on a Scale
Change From Baseline in Asthma Control Questionnaire-5 (ACQ-5) Score
Scores on a ScalePlacebo in Previous Studies/GSK3511294 100 mg SC in Extension StudyGSK3511294 in Previous Studies/GSK3511294 100 mg SC in Extension Study
Week 4-0.28 ± 0.056-0.16 ± 0.039
Week 8-0.22 ± 0.056-0.19 ± 0.039
Week 12-0.28 ± 0.055-0.22 ± 0.038
Week 20-0.16 ± 0.058-0.16 ± 0.040
Week 26-0.14 ± 0.055-0.12 ± 0.038
Week 28-0.23 ± 0.057-0.24 ± 0.039
Week 32-0.35 ± 0.057-0.25 ± 0.040
Week 40-0.24 ± 0.065-0.16 ± 0.045
Week 52-0.15 ± 0.059-0.11 ± 0.041
SecondaryChange From Baseline in St. George's Respiratory Questionnaire (SGRQ) Total Score at Weeks 26 and 52

The SGRQ is a 50-item patient-reported outcome tool used to measure Quality of Life in participants with airway obstruction diseases. The questions are designed to be self-completed by the participant. The total score was calculated by the symptom score, activity and impact score; and summarizing the impact of the disease on overall health status on 0-100 rating scale. Scores are expressed as a percentage of overall impairment where 100 representing worst possible health status and 0 indicating best possible health status. Higher scores indicating greater impairment of quality of life. Baseline was the value at Day 1 of the study. Change from Baseline was defined as value at the indicated time point minus Baseline value. Number of participants with analyzable data for one or more timepoints.

Time frame:
Baseline (Day 1), Weeks 26 and 52
Reported as:
Least squares mean · Scores on a Scale
Change From Baseline in St. George's Respiratory Questionnaire (SGRQ) Total Score at Weeks 26 and 52
Scores on a ScalePlacebo in Previous Studies/GSK3511294 100 mg SC in Extension StudyGSK3511294 in Previous Studies/GSK3511294 100 mg SC in Extension Study
Week 26-5.00 ± 0.939-2.62 ± 0.641
Week 52-4.75 ± 1.043-2.33 ± 0.713
SecondaryChange From Baseline in Pre-Bronchodilator Forced Expiratory Volume in One Second (FEV1) at Weeks 26 and 52

Forced Expiratory Volume in One Second (FEV1) is a measure of lung function and defined as the volume of air that can be forced out in one second after taking a deep breath. FEV1 was measured electronically by spirometry. Baseline was the value at Day 1 of the study. Change from Baseline in pre-bronchodilator FEV1 was defined as value at the indicated time point minus Baseline value. Number of participants with analyzable data for one or more timepoints.

Time frame:
Baseline (Day 1), Weeks 26 and 52
Reported as:
Least squares mean · Liters (L)
Change From Baseline in Pre-Bronchodilator Forced Expiratory Volume in One Second (FEV1) at Weeks 26 and 52
Liters (L)Placebo in Previous Studies/GSK3511294 100 mg SC in Extension StudyGSK3511294 in Previous Studies/GSK3511294 100 mg SC in Extension Study
Week 260.059 ± 0.02070.013 ± 0.0144
Week 520.036 ± 0.0217-0.004 ± 0.0152

Adverse events

Collected over Up to Week 56. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo in Previous Studies/GSK3511294 100 mg SC in Extension Study0/210 (0%)21/210 (10%)82/210 (39%)
GSK3511294 in Previous Studies/GSK3511294 100 mg SC in Extension Study0/419 (0%)38/419 (9.1%)178/419 (42.5%)
Most frequent serious events
Showing 10 of 46
Most frequent serious events
EventPlacebo in Previous Studies/GSK3511294 100 mg SC in Extension StudyGSK3511294 in Previous Studies/GSK3511294 100 mg SC in Extension Study
AsthmaRespiratory, thoracic and mediastinal disorders3/2105/419
Atrial fibrillationCardiac disorders2/2102/419
COVID-19Infections and infestations2/2100/419
PneumoniaInfections and infestations2/2103/419
Intervertebral disc protrusionMusculoskeletal and connective tissue disorders2/2101/419
Lower respiratory tract infectionInfections and infestations0/2102/419
Adams-Stokes syndromeCardiac disorders1/2100/419
Adrenal massEndocrine disorders1/2100/419
Intestinal obstructionGastrointestinal disorders1/2100/419
Oesophageal obstructionGastrointestinal disorders1/2100/419
Most frequent other events
Most frequent other events
EventPlacebo in Previous Studies/GSK3511294 100 mg SC in Extension StudyGSK3511294 in Previous Studies/GSK3511294 100 mg SC in Extension Study
NasopharyngitisInfections and infestations21/21058/419
Upper respiratory tract infectionInfections and infestations25/21045/419
COVID-19Infections and infestations15/21028/419
BronchitisInfections and infestations7/21022/419
HeadacheNervous system disorders7/21018/419
Respiratory tract infectionInfections and infestations3/21016/419
PharyngitisInfections and infestations8/21015/419
RhinitisInfections and infestations8/21013/419
InfluenzaInfections and infestations7/2109/419
Lower respiratory tract infectionInfections and infestations6/21013/419

Baseline characteristics

Baseline characteristics were reported for the Safety Analysis Set which included all participants who received at least one dose of open-label GSK3511294 in this extension study, excluding the participants from the sites with data integrity and GCP violation issues.

Age, Continuous
Age, Continuous(Years)Placebo in Previous Studies/GSK3511294 100 mg SC in Extension StudyGSK3511294 in Previous Studies/GSK3511294 100 mg SC in Extension StudyTotal
Mean53.6 ± 15.8455.5 ± 14.8454.8 ± 15.19
Sex: Female, Male
Sex: Female, Male(Participants)Placebo in Previous Studies/GSK3511294 100 mg SC in Extension StudyGSK3511294 in Previous Studies/GSK3511294 100 mg SC in Extension StudyTotal
Female128248376
Male82171253
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Placebo in Previous Studies/GSK3511294 100 mg SC in Extension StudyGSK3511294 in Previous Studies/GSK3511294 100 mg SC in Extension StudyTotal
WHITE169321490
ASIAN3581116
AMERICAN INDIAN OR ALASKA NATIVE123
BLACK OR AFRICAN AMERICAN51520
08

Study locations

137 sites
  • GSK Investigational Site
    Mobile, Alabama 36608, United States
  • GSK Investigational Site
    Lancaster, California 93534, United States
  • GSK Investigational Site
    Colorado Springs, Colorado 80923, United States
  • GSK Investigational Site
    Lafayette, Colorado 80026, United States
  • GSK Investigational Site
    Coral Gables, Florida 33134, United States
  • GSK Investigational Site
    Hialeah, Florida 33013, United States
  • GSK Investigational Site
    Loxahatchee Groves, Florida 33470, United States
  • GSK Investigational Site
    Miami, Florida 33144, United States
  • GSK Investigational Site
    Miami, Florida 33173, United States
  • GSK Investigational Site
    Miami, Florida 33186, United States
  • GSK Investigational Site
    Orlando, Florida 32806, United States
  • GSK Investigational Site
    Savannah, Georgia 31406, United States
  • GSK Investigational Site
    Normal, Illinois 61761, United States
  • GSK Investigational Site
    Lexington, Kentucky 40509, United States
  • GSK Investigational Site
    Ypsilanti, Michigan 48197, United States
  • GSK Investigational Site
    Northfield, New Jersey 08225, United States
  • GSK Investigational Site
    Toms River, New Jersey 08755, United States
  • GSK Investigational Site
    The Bronx, New York 10461, United States
  • GSK Investigational Site
    Gastonia, North Carolina 28054, United States
  • GSK Investigational Site
    Huntersville, North Carolina 28078, United States
  • GSK Investigational Site
    Winston-Salem, North Carolina 27103, United States
  • GSK Investigational Site
    DuBois, Pennsylvania 15801, United States
  • GSK Investigational Site
    Allen, Texas 75013, United States
  • GSK Investigational Site
    Boerne, Texas 78006, United States
  • GSK Investigational Site
    Dallas, Texas 75225, United States
  • GSK Investigational Site
    Kerrville, Texas 78028, United States
  • GSK Investigational Site
    San Antonio, Texas 78207, United States
  • GSK Investigational Site
    San Antonio, Texas 78229, United States
  • GSK Investigational Site
    Bellingham, Washington 98225, United States
  • GSK Investigational Site
    Coffs Harbour, New South Wales 2450, Australia
  • GSK Investigational Site
    South Brisbane, Queensland 4101, Australia
  • GSK Investigational Site
    Sherwood Park, Alberta T8H 0N2, Canada
  • GSK Investigational Site
    Kamloops, British Columbia V2C 5T1, Canada
  • GSK Investigational Site
    Ajax, Ontario L1S 2J5, Canada
  • GSK Investigational Site
    Ottawa, Ontario K1G 6C6, Canada
  • GSK Investigational Site
    Changsha, Hunan 410013, China
  • GSK Investigational Site
    Changchun, 130021, China
  • GSK Investigational Site
    Changchun, 132011, China
  • GSK Investigational Site
    Chengdu, 610041, China
  • GSK Investigational Site
    Guangzhou, 510080, China
  • GSK Investigational Site
    Guangzhou, 510120, China
  • GSK Investigational Site
    Guangzhou, 510150, China
  • GSK Investigational Site
    Guangzhou, 510180, China
  • GSK Investigational Site
    Haikou, 570311, China
  • GSK Investigational Site
    Hangzhou, 310009, China
  • GSK Investigational Site
    Hefei, 230001, China
  • GSK Investigational Site
    Hohhot, 10017, China
  • GSK Investigational Site
    Jinan, 250014, China
  • GSK Investigational Site
    Shanghai, 200040, China
  • GSK Investigational Site
    Shanghai, 200090, China
  • GSK Investigational Site
    Shenyang, 110004, China
  • GSK Investigational Site
    Shenyang, 110016, China
  • GSK Investigational Site
    Ürümqi, 830054, China
  • GSK Investigational Site
    Wenzhou, 323027, China
  • GSK Investigational Site
    Wuhan, 430030, China
  • GSK Investigational Site
    Xuzhou, 221006, China
  • GSK Investigational Site
    Brno, 625 00, Czechia
  • GSK Investigational Site
    Hradec Králové, 500 05, Czechia
  • GSK Investigational Site
    Jindřichův Hradec, 377 01, Czechia
  • GSK Investigational Site
    Strakonice, 38601, Czechia
  • GSK Investigational Site
    Tábor, 390 02, Czechia
  • GSK Investigational Site
    Teplice, 415 01, Czechia
  • GSK Investigational Site
    Caen, 14033, France
  • GSK Investigational Site
    Cholet, 49300, France
  • GSK Investigational Site
    Marseille, 13015, France
  • GSK Investigational Site
    Strasbourg, 67091, France
  • GSK Investigational Site
    Berlin, 10367, Germany
  • GSK Investigational Site
    Frankfurt, 60389, Germany
  • GSK Investigational Site
    Hamburg, 22299, Germany
  • GSK Investigational Site
    Koblenz, 56068, Germany
  • GSK Investigational Site
    Leipzig, 04275, Germany
  • GSK Investigational Site
    Magdeburg, 39120, Germany
  • GSK Investigational Site
    Neu-Isenburg, 63263, Germany
  • GSK Investigational Site
    Gödöllő, 2100, Hungary
  • GSK Investigational Site
    Mosonmagyaróvár, 9200, Hungary
  • GSK Investigational Site
    Szigetvár, 7900, Hungary
  • GSK Investigational Site
    Brescia, 25123, Italy
  • GSK Investigational Site
    Foggia, 71122, Italy
  • GSK Investigational Site
    Messina, 98158, Italy
  • GSK Investigational Site
    Milan, 20122, Italy
  • GSK Investigational Site
    Monserrato CA, 09042, Italy
  • GSK Investigational Site
    Palermo, 90127, Italy
  • GSK Investigational Site
    Pavia, 27100, Italy
  • GSK Investigational Site
    Roma, 168, Italy
  • GSK Investigational Site
    Rozzano MI, 20089, Italy
  • GSK Investigational Site
    Siena, 53100, Italy
  • GSK Investigational Site
    Varese, 21049, Italy
  • GSK Investigational Site
    Aichi, 470-1192, Japan
  • GSK Investigational Site
    Aichi, 489-8642, Japan
  • GSK Investigational Site
    Chiba, 275-8580, Japan
  • GSK Investigational Site
    Fukuoka, 802-0052, Japan
  • GSK Investigational Site
    Fukuoka, 811-1394, Japan
  • GSK Investigational Site
    Fukuoka, 813-0017, Japan
  • GSK Investigational Site
    Fukushima, 960-1295, Japan
  • GSK Investigational Site
    Hiroshima, 734-8530, Japan
  • GSK Investigational Site
    Hokkaido, 053-8506, Japan
  • GSK Investigational Site
    Hokkaido, 064-0804, Japan
  • GSK Investigational Site
    Kagawa, 761-8073, Japan
  • GSK Investigational Site
    Kagawa, 762-8550, Japan
  • GSK Investigational Site
    Kagoshima, 890-8520, Japan

Showing the first 100 of 137 sites across 14 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Data sharing details ↗ · clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2022 to primary completion in May 2025, 38 months.

Results were first posted in Jan 2026, 7 months after primary completion.

Of 173 industry-sponsored phase 3 interventional studies under Asthma, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's 38 months is above that.

Counting every sponsor, half of 205 studies reached it within 27 months; a quarter within 14 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 8, 2022
First posted
Feb 17, 2022
StartActual
Mar 1, 2022
Primary completionActual
May 19, 2025
CompletionActual
May 19, 2025
Results first posted
Jan 15, 2026
Last update
Jan 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05243680
Lead sponsor
GlaxoSmithKline
Collaborators
IQVIA Pty Ltd
Responsible party
Sponsor
First posted
Feb 17, 2022
Start date
Mar 1, 2022
Primary completion
May 19, 2025
Completion
May 19, 2025
Results posted
Jan 15, 2026
Last update
Jan 15, 2026

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Depemokimab

Start the discussion